证券代码：600645 证券简称：中源协和 公告编号：2023-044 中源协和细胞基因工程股份有限公司 2023 年第一次临时股东大会决议公告 一、 会议召开和出席情况 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 | 1、出席会议的股东和代理人人数 | 9 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 108,847,946 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 23.2606 | 重要内容提示： (四) 表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次会议是否有否决议案：无 会议采用现场投票和网络投票相结合的表决方式，符合《公司法》和《公司 (一) 股东大会召开的时间：2023 年 11 月 13 日 (二) 股东大会召开的地点：天津市滨海高新区华苑产业区梅苑路 12 号公司会 议室 (三) 出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： 章程》的有关规定，经公司半数以上董事推举， ...

Financial Performance - The company's operating revenue for Q3 2023 was CNY 404,288,544.80, a decrease of 0.77% compared to the same period last year[5]. - Net profit attributable to shareholders was CNY 49,836,990.44, reflecting a slight increase of 0.24% year-on-year[5]. - The net profit excluding non-recurring gains and losses reached CNY 46,420,855.62, up by 5.25% compared to the previous year[5]. - Year-to-date net profit attributable to shareholders increased by 15.68% to CNY 132,511,715.75[5]. - Total operating revenue for the first three quarters of 2023 reached ¥1,202,361,554.62, a slight increase from ¥1,176,215,892.32 in the same period of 2022, representing a growth of approximately 2.1%[19]. - Net profit for the first three quarters of 2023 was ¥129,363,556.18, up from ¥113,460,668.07 in 2022, reflecting an increase of approximately 14.0%[21]. - Earnings per share for the third quarter of 2023 were ¥0.28, compared to ¥0.24 in the same quarter of 2022, marking a growth of 16.7%[21]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 5,422,684,073.67, representing a growth of 2.61% from the end of the previous year[6]. - As of September 30, 2023, the company's total assets amounted to RMB 5,422,684,073.67, an increase from RMB 5,284,619,414.55 in December 2022, reflecting a growth of approximately 2.62%[14]. - The total liabilities as of the end of the third quarter of 2023 amounted to ¥1,607,328,973.59, a slight decrease from ¥1,630,964,993.11 at the end of 2022[20]. - The total current liabilities were RMB 1,458,579,250.56, slightly decreased from RMB 1,471,494,581.46 in December 2022, showing a reduction of about 0.88%[15]. - The total equity attributable to shareholders of the parent company increased to ¥3,699,101,217.49 from ¥3,555,802,379.28, representing a growth of approximately 4.0%[20]. Cash Flow - The company reported a cash flow from operating activities of CNY 185,611,359.85, an increase of 4.10% year-to-date[5]. - Cash flow from operating activities for the first three quarters of 2023 was ¥1,237,616,152.41, compared to ¥1,201,322,207.24 in 2022, indicating an increase of about 3.0%[23]. - The net cash inflow from operating activities for Q3 2023 was $185,611,359.85, an increase from $178,308,231.45 in Q3 2022, representing a growth of approximately 1.8%[24]. - The total cash and cash equivalents at the end of Q3 2023 amounted to $1,509,919,261.57, up from $1,317,810,007.20 in Q3 2022, reflecting an increase of approximately 14.5%[25]. Investments and Expenses - Total cash inflow from investment activities was $15,775,400.58, compared to $3,025,864.67 in the same period last year, indicating a significant increase[24]. - The net cash outflow from investment activities was -$61,959,285.25, an improvement from -$71,251,901.56 in Q3 2022[24]. - Research and development expenses for the first three quarters of 2023 were ¥117,503,490.16, up from ¥109,497,085.50 in 2022, reflecting an increase of approximately 7.3%[20]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 37,602[10]. - The company's goodwill remained stable at RMB 702,913,535.62, unchanged from December 2022[15]. Other Information - The company has not provided specific guidance for future performance or new product developments in the current report[13]. - The company reported a decrease in other comprehensive income for the third quarter of 2023, with a net amount of ¥14,540,513.38 compared to a loss of ¥31,990,174.02 in the same period of 2022[21]. - The impact of exchange rate changes on cash and cash equivalents was $14,959,924.71, compared to $42,921,457.97 in the previous year[25].

证券代码：600645 证券简称：中源协和 公告编号：2023-032 1 中源协和细胞基因工程股份有限公司 关于参加 2023 年度天津辖区上市公司半年报业绩说 明会暨投资者网上集体接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●活动时间：2023年9月5日（星期二）13:30-16:50 公司与投资者网上交流时间：2023年9月5日（星期二）15:10-16:40 ●参与方式：投资者可登录"全景路演"网站（http://rs.p5w.net），或 关注微信公众号：全景财经，或下载全景路演APP，参与本次活动。 ●召开方式：网络方式召开 一、会议情况 为进一步加强与投资者的沟通交流，公司将参加由天津证监局、天津上市公 司协会与深圳市全景网络有限公司联合举办的"2023年度天津辖区上市公司半年 报业绩说明会暨投资者网上集体接待日活动"。本次活动将采用网络远程的方式 举行，届时公司将在线就公司业绩、公司治理、发展战略、经营状况和可持续发 展等投资者关心的问题，与投资者进行沟通与交流，欢迎广大投 ...

截至报告期末普通股股东总数(户) 38,926 截至报告期末表决权恢复的优先股股东总数（户） 0 41 / 162 (三) 战略投资者或一般法人因配售新股成为前十名股东 □适用 √不适用 (二) 董事、监事、高级管理人员报告期内被授予的股权激励情况 □适用 √不适用 第八节 优先股相关情况 二、可转换公司债券情况 □适用 √不适用 第十节 财务报告 合并资产负债表 | --- | --- | --- | --- | |-----------------------------|---------|------------------|------------------| | | | | | | 使用权资产 | 七、 25 | 114,592,226.20 | 115,785,611.55 | | 无形资产 | 七、 26 | 108,912,436.62 | 111,730,278.37 | | 开发支出 | 七、 27 | 33,619,815.91 | 26,197,887.51 | | 商誉 | 七、 28 | 702,913,535.62 | 702,913,535.62 | | 长期待摊费用 | ...

Financial Performance - The company's audited net profit for 2022 was -56.21 million RMB, resulting in a cumulative undistributed profit of -213 million RMB as of December 31, 2022, leading to no profit distribution to shareholders [5]. - Operating revenue for 2022 was 1,554.89 million RMB, a 1.27% increase from 2021 [19]. - Net profit attributable to shareholders decreased by 27.26% year-on-year, primarily due to the previous year's fair value increase of Aceso's fund holdings [21]. - The cash flow from operating activities for 2022 was 261.89 million RMB, down 18.40% from 2021 [19]. - The basic earnings per share for 2022 was 0.24 RMB, a decrease of 27.27% from 2021 [21]. - The weighted average return on net assets for 2022 was 3.23%, down 1.29 percentage points from the previous year [21]. - The company reported a net asset value attributable to shareholders of 3,555.80 million RMB at the end of 2022, an increase of 2.67% from the end of 2021 [19]. - The company reported non-recurring gains and losses totaling 8.95 million yuan for 2022, a significant decrease from 100.27 million yuan in 2021 [25]. - The net profit attributable to shareholders for Q3 was 49.72 million yuan, while Q4 reported a loss of 1.56 million yuan [24]. - The company reported a significant decrease in financial expenses by 77.23%, attributed to increased interest income from deposits [81]. Research and Development - R&D investment totaled CNY 158.68 million in 2022, representing 10.21% of operating revenue, with R&D personnel increasing to 248, accounting for 10.63% of total staff [44]. - The company is actively conducting 74 research projects related to stem cell research and product development, with 38 projects completed [96]. - The company has developed a diverse product range, including over 27,000 human-derived proteins and 140,000 primary antibodies, positioning itself as a leading provider in the research field [72]. - The company aims to enhance its competitive edge by expanding its clinical cooperation and product lines, focusing on precision medicine [126]. - The company plans to push forward with stem cell drug applications and clinical trials, with IND acceptance for multiple indications [127]. Market Trends and Opportunities - The Chinese cell therapy market is projected to grow from 1.3 billion RMB in 2021 to 58.4 billion RMB by 2030, with an annual growth rate of 53% [116]. - The CAR-T therapy market in China is expected to expand from 200-300 million RMB in 2021 to 28.7 billion RMB by 2030 [116]. - The in vitro diagnostics market in China is expected to grow rapidly, with the company focusing on product quality and innovation to maintain a competitive advantage [138]. - The global life science reagent market reached $17.5 billion in 2019 and is expected to grow to $24.6 billion by 2024, with the Chinese market projected to reach ¥26 billion by 2024 [63]. Strategic Initiatives - The company is actively pursuing market expansion and new product development in the precision medicine sector, enhancing its upstream and downstream synergy effects [113]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market reach, with a budget of 200 million set aside for this purpose [154]. - The company signed a strategic cooperation framework agreement with the Tianjin Cell Ecology Haihe Laboratory to enhance innovation and industrialization of cell-derived products [76]. - The company is collaborating with key hospitals to establish a research and development transformation platform, with multiple clinical studies currently underway [42]. Governance and Compliance - The company adheres to strict governance practices, ensuring compliance with laws and protecting shareholder rights [141]. - The board of directors consists of 9 members, including 3 independent directors, ensuring proper governance and oversight [143]. - The company has established a comprehensive performance evaluation standard and procedure for senior management to promote sustainable development [144]. - The company has implemented measures to ensure compliance with insider information management regulations [145]. Environmental Responsibility - Wuxi Aorui Company discharged 13,284.96 tons of domestic sewage and 1,229.28 tons of industrial wastewater in 2022, with COD emissions of 2.655 tons and 0.117 tons respectively [184]. - Both companies' wastewater and air emissions were reported to be below national standards during the reporting period [185][187]. - The companies are committed to complying with environmental protection laws and ensuring proper waste treatment and emissions standards [195]. Challenges and Risks - The company is facing industry policy risks due to potential future regulations in the fields of stem cells and gene testing, which may impact operations [133]. - Talent retention is a concern as the company expands, with strategies in place to align management and core talent interests to mitigate risks of talent loss [134]. - The newborn storage business is dependent on birth rates, which are declining, prompting the company to enhance service quality and expand into adult cell storage [137].

Financial Performance - Total operating revenue for Q1 2023 was ¥377,745,248.80, a decrease of 4.4% compared to ¥394,174,107.03 in Q1 2022[22]. - Total operating costs for Q1 2023 were ¥323,064,529.03, down 3.5% from ¥335,382,040.09 in Q1 2022[22]. - Net profit for Q1 2023 was ¥35,256,628.40, a slight decrease of 2.7% from ¥36,246,721.16 in Q1 2022[23]. - The net profit attributable to shareholders for Q1 2023 was CNY 37,373,824.55, an increase of 4.33% year-over-year[30]. - The total comprehensive income for Q1 2023 was ¥23,039,552.43, compared to a loss of ¥42,196,397.05 in Q1 2022[23]. - Basic earnings per share remained stable at ¥0.08 for both Q1 2023 and Q1 2022[23]. - The company reported a basic earnings per share of CNY 0.08 for Q1 2023, unchanged from the previous year[30]. Assets and Liabilities - The total assets as of Q1 2023 were 5,247,791,551.14 RMB, a decrease from 5,284,619,414.55 RMB in the previous period[19]. - The total non-current assets were 2,950,834,014.00 RMB, down from 2,974,590,727.49 RMB[19]. - The total current liabilities decreased to 1,412,669,461.64 RMB from 1,471,494,581.46 RMB[19]. - The total liabilities amounted to ¥1,571,850,968.19, a decrease from ¥1,630,964,993.11 in the previous period[20]. - The equity attributable to shareholders of the parent company was ¥3,577,205,736.94, an increase from ¥3,555,802,379.28[20]. - The equity attributable to shareholders increased to CNY 3,577,205,736.94, reflecting a growth of 0.60% year-over-year[31]. Cash Flow - The net cash flow from operating activities for Q1 2023 was CNY 27,030,268.28, down by 10.09% compared to Q1 2022[30]. - Cash received from operating activities totaled CNY 402,970,860.77 in Q1 2023, slightly up from CNY 402,509,153.30 in Q1 2022[25]. - Cash paid for goods and services in Q1 2023 was CNY 102,356,677.01, down from CNY 106,814,353.67 in the same period last year[25]. - Investment activities generated a net cash flow of -$22.64 million, compared to -$24.44 million in the previous period, indicating an improvement of approximately 7.3%[46]. - Cash outflow from investment activities totaled $32.65 million, up from $24.52 million year-over-year, representing a 33.1% increase[46]. - Cash flow from financing activities resulted in a net outflow of -$9.74 million, compared to -$8.74 million in the previous period, reflecting an 11.4% increase in outflow[46]. - The ending balance of cash and cash equivalents was $1.37 billion, slightly down from $1.19 billion in the previous year[46]. Research and Development - R&D expenses increased to ¥33,453,290.77 in Q1 2023, up 15.5% from ¥29,027,540.94 in Q1 2022[22]. - Clinical trial applications for the VUM02 injection have been accepted, with approvals for two indications received in February and April 2023[15]. Other Income and Expenses - Government subsidies recognized in the current period amounted to 1,075,325.83 RMB[5]. - The impairment provision reversal for receivables and contract assets was 139,815.00 RMB[5]. - Other operating income and expenses, excluding the above items, totaled 257,734.20 RMB[5]. - The total non-recurring profit and loss items amounted to 941,882.66 RMB after tax and minority interest adjustments[5]. - The company reported a decrease in other comprehensive income after tax of ¥12,217,075.97 compared to a loss of ¥78,443,118.21 in the previous year[23].

Financial Performance - The company's operating revenue for Q3 2022 was ¥407,415,406.55, representing a year-on-year increase of 4.01%[6] - The net profit attributable to shareholders for Q3 2022 was ¥49,718,296.95, a decrease of 37.94% compared to the same period last year[6] - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 111.58% year-on-year, indicating strong growth in reagent business revenue[13] - The basic earnings per share for Q3 2022 was ¥0.10, down 41.18% from the previous year[9] - Net profit for the third quarter of 2022 was ¥113,460,668.07, down from ¥194,586,517.04 in the same quarter of 2021, reflecting a decrease of approximately 41.7%[33] - The company reported a total comprehensive income of ¥81,470,494.05 for the third quarter of 2022, compared to ¥186,621,508.15 in the same quarter of 2021, a decrease of about 56.4%[35] - The company experienced a decrease in investment income, reporting ¥2,188,625.17 in 2022 compared to ¥20,486,959.81 in 2021, a decline of about 89.3%[30] Assets and Liabilities - The total assets at the end of the reporting period were ¥5,226,937,505.02, an increase of 3.85% compared to the end of the previous year[9] - As of September 30, 2022, the company's total assets amounted to RMB 5,226,937,505.02, an increase from RMB 5,033,377,672.10 as of December 31, 2021, representing a growth of approximately 3.84%[22] - The total liabilities of the company were RMB 1,596,406,723.50, compared to RMB 1,500,617,384.63 at the end of 2021, reflecting a rise of approximately 6.38%[28] - The total owner's equity was RMB 3,630,530,781.52, reflecting a stable position compared to the previous year[28] - The company’s total liabilities and equity increased to ¥5,226,937,505.02 in 2022 from ¥5,033,377,672.10 in 2021, reflecting a growth of approximately 3.8%[30] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥178,308,231.45, reflecting a decrease of 23.34%[9] - The net cash flow from operating activities was 178,308,231.45, a decrease of 23.3% compared to 232,588,634.00 from the previous period[40] - Total cash inflow from financing activities was 17,500,000.00, significantly higher than 692,100.00 in the previous period[42] - The net cash flow from investing activities was -71,251,901.56, an improvement from -92,456,340.77 in the previous period[40] - Cash and cash equivalents at the end of the period reached 1,317,810,007.20, up from 1,176,968,867.46 in the previous period[42] - The total cash outflow from financing activities was 39,740,742.26, compared to 22,629,667.81 in the previous period, indicating increased financial obligations[42] - The cash inflow from operating activities totaled 1,235,684,087.35, slightly down from 1,245,397,088.82 in the previous period[40] - The cash outflow for purchasing goods and services was 299,916,803.09, an increase from 283,025,699.27 in the previous period[40] - The company received tax refunds amounting to 4,749,499.19, compared to 1,193,803.99 in the previous period, showing improved tax recovery[40] - The cash inflow from investment activities was 3,025,864.67, a significant decrease from 71,836,563.12 in the previous period[40] - The net increase in cash and cash equivalents for the period was 127,737,045.60, compared to 116,649,488.84 in the previous period[42] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 38,183[14] - The largest shareholder, Tianjin Deyuan Health Management Co., Ltd., held 12.14% of the shares, with a significant portion pledged[16] Research and Development - Research and development expenses for the first three quarters of 2022 were ¥109,497,085.50, up from ¥102,165,541.66 in 2021, marking an increase of about 7.3%[30]

Financial Performance - The company's operating revenue for the first half of 2022 was approximately RMB 768.80 million, a slight increase of 0.09% compared to RMB 768.10 million in the same period last year[21]. - The net profit attributable to shareholders of the listed company decreased by 41.44% to RMB 64.83 million from RMB 110.70 million year-on-year[21]. - The net profit after deducting non-recurring gains and losses was RMB 54.22 million, down 25.17% from RMB 72.45 million in the previous year[21]. - The net cash flow from operating activities was RMB 105.78 million, a decrease of 13.60% compared to RMB 122.43 million in the same period last year[21]. - Basic earnings per share decreased by 41.67% to RMB 0.14 from RMB 0.24 in the same period last year[22]. - The weighted average return on net assets was 1.87%, down 1.29 percentage points from 3.16% in the previous year[25]. - The company achieved operating revenue of 769 million RMB, a year-on-year increase of 0.09%[26]. - The decline in net profit was primarily due to the previous year's full exemption of the "U.S. PPP loan" and a decrease in the fair value changes of investments in associated companies[26]. - The company reported a gross margin of 74.82% in the service sector, which decreased by 2.62% compared to the previous year[53]. - In the manufacturing sector, the gross margin was 65.92%, reflecting a decrease of 0.95% year-on-year[53]. Assets and Liabilities - The total assets at the end of the reporting period were RMB 5.11 billion, an increase of 1.53% from RMB 5.03 billion at the end of the previous year[21]. - The net assets attributable to shareholders of the listed company increased by 0.41% to RMB 3.48 billion from RMB 3.46 billion at the end of the previous year[21]. - Total assets increased to CNY 5,110,355,629.70, up from CNY 5,033,377,672.10, representing a growth of 1.53%[178]. - Current liabilities rose to CNY 1,415,375,843.32, compared to CNY 1,395,646,643.11, reflecting an increase of 1.27%[178]. - Total liabilities amounted to CNY 1,547,942,962.15, up from CNY 1,500,617,384.63, indicating a growth of 3.15%[178]. - Shareholders' equity increased to CNY 3,562,412,667.55 from CNY 3,532,760,287.47, marking a rise of 0.84%[178]. Research and Development - The company is actively advancing clinical projects and cell drug development to improve its research and development capabilities[30]. - R&D expenses decreased by 7.69% to 64.51 million RMB compared to the previous year[62]. - The company has established a GMP-grade iPSC library to accelerate the process of allogeneic cell therapy[49]. - The company plans to focus on market expansion and new product development as part of its future strategy[184]. - The company is focused on developing new products in the in vitro diagnostic sector to maintain market competitiveness[88]. Market and Industry Trends - The company operates in the "precision medicine" sector, focusing on cell detection, in vitro diagnostics, and stem cell applications[30]. - The domestic in vitro diagnostic market is expected to maintain rapid growth due to factors such as economic development, healthcare reform, aging population, and increased disposable income, with significant market potential ahead[91]. - The government is prioritizing the development of immune cell therapy and gene therapy, indicating a strong future market for these technologies[33]. - The emphasis on early disease prevention and health services aligns with the growing consumer demand for healthcare solutions[33]. Corporate Governance and Compliance - The company has established independent financial and operational structures to maintain the integrity of its assets and financial decisions[114]. - The company has committed to not engaging in competitive business activities with the listed company and will ensure compliance with relevant regulations regarding related party transactions[111]. - The company guarantees the independence of its financial personnel, ensuring they do not hold positions or receive compensation from related enterprises[126]. - The company has established a robust organizational structure to ensure independent governance and decision-making processes[120]. Legal and Regulatory Matters - The company has ongoing significant litigation regarding a land use rights transfer dispute, with a judgment requiring a repayment of 71.21 million yuan from Singapore Huide Investment Holdings Co., Ltd.[145]. - The company is involved in a lawsuit concerning a 67% equity transfer dispute, with a settlement requiring a payment of 30 million yuan, of which only 1 million yuan has been received to date, leaving a balance of 29 million yuan outstanding[145]. - There are no significant guarantees or violations reported during the reporting period[142]. - The company has not faced any standard audit opinion issues in the previous annual report[145]. Social Responsibility - The company has been recognized for its social responsibility efforts, including the establishment of the "Zhongyuan Harmony Life Science Award" to support young scientists[44].

证券代码：600645 证券简称：中源协和 公告编号：2022-047 中源协和细胞基因工程股份有限公司 关于参加 2022 年度天津辖区上市公司半年报业绩说 明会与投资者网上集体接待日活动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●召开时间：2022年9月6日（星期二）13:40-16:40 ●召开地点：全景路演（http://rs.p5w.net） ●召开方式：网络方式召开 一、会议情况 为进一步加强与投资者的沟通交流，公司定于2022年9月6日（星期二） 13:40-16:40在全景路演参加2022年度天津辖区上市公司半年报业绩说明会与投 资者网上集体接待日活动。本次活动将采用网络远程的方式举行，投资者可登录 全景路演（http://rs.p5w.net）参与本次互动交流，与公司互动交流时间为 15:00-16:30。 二、召开时间和方式 时间：2022年9月6日（星期二）13:40-16:40 地点：全景路演（http://rs.p5w.net） 方式：网络方式召开 三、公司出席人员 公司出 ...

Financial Performance - The company's audited net profit for 2021 was CNY 85.0134 million, with a cumulative undistributed profit of -CNY 156 million as of December 31, 2021, resulting in no profit distribution to shareholders[7]. - Total operating revenue for 2021 reached CNY 1.535 billion, representing a 16.41% increase compared to CNY 1.319 billion in 2020[25]. - The net profit attributable to shareholders of the listed company was CNY 155.32 million, a significant recovery from a loss of CNY 126.86 million in 2020[25]. - The net cash flow from operating activities for 2021 was CNY 320.96 million, reflecting a 31.35% increase from CNY 244.35 million in 2020[25]. - The net profit after deducting non-recurring gains and losses was CNY 55.05 million, compared to a loss of CNY 211.75 million in the previous year[25]. - The company did not implement capital reserve transfers to increase share capital or other forms of distribution due to negative retained earnings[7]. - The net profit attributable to shareholders of the listed company turned from a loss to a profit, mainly due to an increase in revenue and a reduction in goodwill impairment loss of 265 million yuan from the previous year[27]. - Basic earnings per share improved to 0.33 yuan, compared to a loss of 0.27 yuan in the previous year[27]. - The weighted average return on net assets increased by 8.28 percentage points to 4.52%[27]. - The company achieved operating revenue of CNY 1.535 billion, an increase of 16.41% compared to the previous year[77]. - The net profit attributable to shareholders was CNY 155.32 million, with a net profit of CNY 55.05 million after deducting non-recurring gains and losses, marking a turnaround from losses in the previous year[77]. Research and Development - Research and development investment accounted for 9.55% of revenue, significantly higher than the industry average in 2020[37]. - The company invested CNY 146.70 million in R&D in 2021, representing 9.55% of total revenue, which is above the industry average[45]. - The number of R&D personnel increased to 206 in 2021, accounting for 9.23% of the total workforce[45]. - The company completed 54 out of 116 R&D projects during the reporting period, including 48 projects related to stem cell research and product development[45]. - The company has established a comprehensive research and development system, collaborating with renowned hospitals and experts to advance stem cell clinical projects and drug development[69]. - The company aims to enhance R&D capabilities and improve operational efficiency across its precision medical industry chain[65]. - The company is committed to advancing research in stem cell technology, as indicated by its involvement in national key research projects[58]. - The company has developed a leading antibody research and production platform, offering a wide range of protein products and solutions in the research field[69]. Market Expansion and Strategy - The company aims to strengthen its position in the cell and gene therapy sector, which is seen as a key growth area in the biopharmaceutical industry[37]. - The company is actively collaborating with agents, insurance, and banking clients to enhance its market presence and professional image in adult cell storage[59]. - The company is focused on expanding its market presence in both domestic and international pathology diagnosis markets[63]. - The company is exploring innovative cooperation models with top-tier hospitals to enhance industrial development[76]. - The company is expanding its market presence in Asia, targeting a 10% market share by the end of the next fiscal year[163]. - The company plans to enhance its immune cell storage business as a new growth point, focusing on product design, agency policies, and optimizing online business systems, particularly in mature markets like Shanghai, Zhejiang, Hubei, and Henan[134]. Clinical and Product Development - The company is advancing clinical approval for two targeted drug screening kits for lung and colorectal cancer, with nearly 50% of sample enrollment completed[42]. - The company is conducting a clinical trial for mesenchymal stem cells, with 31 out of 36 participants enrolled for the treatment of chronic periodontitis[48]. - The CNCT19 cell injection, developed by a subsidiary, has entered Phase II clinical trials for acute lymphoblastic leukemia and non-Hodgkin lymphoma, and received orphan drug designation from the FDA[48]. - The company has successfully obtained clinical research approval for umbilical cord mesenchymal stem cells to treat refractory diabetic peripheral neuropathy[48]. - The company has completed the filing of multiple clinical research projects in collaboration with various hospitals, enhancing its research capabilities[76]. Financial Management and Governance - The total remuneration paid to all directors, supervisors, and senior management during the reporting period amounted to CNY 12.7026 million[177]. - The company implemented a director and supervisor allowance system, with the remuneration plan for senior management approved by the board's remuneration and assessment committee[177]. - The company faced regulatory penalties, including a warning letter issued by the China Securities Regulatory Commission to the former actual controller for non-operating fund occupation[178]. - The company has maintained compliance with its articles of association regarding profit distribution policies[197]. - The independent directors have provided their opinions on the profit distribution plan, confirming its legality and compliance[197]. Operational Efficiency - The company has optimized its quality management system to enhance product quality and operational efficiency, including improvements in NK cell preparation processes[49]. - The establishment of a financial shared service center is underway to enhance operational efficiency and risk management[50]. - The online platform for the life bank has been upgraded, resulting in improved operational efficiency and customer binding rates[50]. - The company is focused on operational efficiency improvements to strengthen its industry position as it expands its adult cell storage business from broad coverage to targeted key regions[59]. Industry Trends and Challenges - The biopharmaceutical industry is witnessing a shift towards more standardized practices and increased emphasis on endogenous innovation, with significant advancements in new technologies and drug approvals[123]. - The domestic clinical research landscape for stem cell therapy is robust, with 111 projects registered, covering various medical categories[126]. - The in vitro diagnostic market in China is expected to grow rapidly due to economic development, healthcare reform, and increasing disposable income, with significant competition emerging[144]. - The company faces risks related to industry policies, particularly in advanced technologies like stem cells and gene testing, which may be subject to future regulatory changes[140].